anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
FIELD: medicine, anesthesiology, resuscitation, surgery. SUBSTANCE: method deals with treating patients suffering diseases accompanied by severe endotoxicosis. One should carry out discrete eplasmapheresis by separating plasma against erythrocytic mass and substituting the volume of removed plasma with donor&#39;s one, moreover, before returning into patient&#39;s body erythrocytic mass should be treated with ozonized isotonic solution of sodium chloride at 200 ml volume and ozone concentration in solution being 2 mg/l. The present innovation enables to decrease toxicity of plasma and erythrocytes that leads to complete interruption of endotoxicosis. EFFECT: higher efficiency of therapy. 1 cl, 3 ex, 2 tbl
Substituted b -aminoethyl benzene compounds of formula &lt;FORM:0796731/IV (b)/1&gt; in which R1 and R2, if not joined, are different and represent a hydroxy radical or an alkoxy radical containing 1-5 carbon atoms, or R1 and R2, if joined together, represent a methylenedioxy or ethylenedioxy radical, and in which R3 represents hydrogen or a methyl radical and R4 a methyl radical, are prepared by methylation of the corresponding primary amines, for example by reaction with formic acid followed by reduction with lithium aluminium hydride. Compounds specified include N-methyl-3,4-methylene dioxy-b -aminoethyl benzene, N,N - dimethyl - 3,4 - methylene dioxy - b  - aminoethyl benzene and N-methyl-3,4-ethylene-dioxy-b -aminoethyl benzene.  These compounds and their acid addition salts may be used in pharmaceutical compositions.ALSO:An antitussive composition comprises a compound of formula &lt;FORM:0796731/VI/1&gt; in which R1 and R2, if not joined, are different and represent a hydroxy radical or an alkoxy radical containing from 1-5 carbon atoms, or R1 and R2 if joined together represent a methylenedioxy or ethylenedioxy radical, and R3-R4 each represents hydrogen or a methyl radical, or an acid salt of such compound, and (a) an orally administrable solid pharmaceutical carrier, or (b) an orally administrable liquid pharmaceutical carrier including a sweetening or flavouring agent, an expectorant or glycerine.  The preferred compounds are those of the N-methyl series, such as N-methyl-3,4-methylenedioxy-b -aminoethyl benzene, N - methyl - 3,4 - ethylene-dioxy-b -aminoethyl benzene, and N-methyl-3-hydroxy - 4 - methoxy - b  - aminoethyl benzene.  Other specified compounds include N,N-dimethyl - 3,4 - methylenedioxy - b  - aminoethyl benzene and 3-methoxy-4-hydroxy-b -aminoethyl benzene.  The solid compositions may be prepared in tablet, capsule or powder form using adjuvants and carriers such as lactose, starch and magnesium stearate.  In an example a tablet composition comprising N-methyl-3,4-methylene-dioxy-b -aminoethyl benzene hydrochloride, starch, magnesium stearate and granules made of a lactose-starch-sucrose mixture is described.
The process for preparing of ophthalmic inserts consisted of water-soluble solid, was described.  It was necessary for the medical treatment during the dryness of the eyeball.  It consists of water soluble polymer selected in the mixt. of cellulose deriv., natural gums, starch deriv., dextrose, polyalkylene glycol, poly vinyl methyl ether, polyethylene oxide, &amp; xanthane gum, or their mixtures.  The selected polymeric powder is compressed and molded through the pressing die.  The surface area of the ophthalmic inserts. not contained drugs, is 5-800 mm2,, and it&#39;s length is 1-30 mm, and it&#39;s breadth and height is 0.25-30 mm.
PURPOSE:A hair cosmetic, containing a quaternary ammonium salt, phosphoric acid ester and aliphatic higher alcohol and having improved effect on impartment of tensity and elasticity without deteriorating the feeling of the hair. CONSTITUTION:A hair cosmetic containing one or two or more of quaternary ammonium salts expressed by formula I (one or two of R1-R4 are 8-24C straight or branched chain alkyl or hydroxyalkyl and the rest are methyl, ethyl, benzyl, etc.; X&lt;-&gt; is anion), one or two or more of phosphoric acid esters expressed by formula II (R5 is 10-22C straight-chain alkyl, hydroxyalkyl, etc.; Y is formula III or Z; R6 is H or methyl; Z is H, alkali metal, etc.; l is 0-8) and one or two or more of 18-24C straight-chain saturated or unsaturated aliphatic higher alcohols. The hair cosmetic is capable of producing effect on impartment of tensity and elasticity without deteriorating the feeling in any types thereof and utilizable for various applications, e.g. hair rinse, hair lotion, etc.
The present invention relates to Acipenser Qiankun decoction for preventing and treating atypical pneumonia, which is prepared to prevent and treat atypical pneumonia popular in a plurality of areas at present. Cotton root, bryozoatum or dry suakwa and dandelion are mainly used, are matched into a No. 1 prescription and a No. 2 prescription by using three kinds of medicines in an auxiliary mode, and are prepared into decoction and granular electuary. The present invention has the functions of strong pathogen resistance, virus resistance, exterior syndrome relief, heat clearness and toxicity removal, cough stop, phlegm elimination and antiasthmatic action. The present invention is used for preventing &#39; atypical pneumonia&#39; and treating patients with &#39;atypical pneumonia&#39;. The decoction and the granular electuary prepared by the present invention have the functions of strong pathogen resistance, virus resistance, exterior syndrome relief, heat clearness and toxicity removal, cough stop, phlegm elimination and antiasthmatic action. Through a test, the treatment effect of the decoction and the granular electuary is obvious.
A method and system for generating a personalized health management recommendation for a user. During operation, the system obtains first physiological data generated by a wearable device worn by the user that indicates a physiological condition of the user. The system then generates a prediction model for the user based on the first physiological data. Next, the system obtains real-time physiological data generated by the wearable device. The system may generate a prediction by analyzing the real-time physiological data to determine whether the user&#39;s physiological condition exceeds a threshold parameter according to the prediction model. Upon determining that the threshold parameter has been exceeded, the system may select a recommendation and send the recommendation message to the user&#39;s mobile device.
FIELD: peptide chemistry. SUBSTANCE: invention relates to dimers of &#34;clover&#34; peptides containing their solitary domains in the form of clover leaf and so constituting human or rat ITF or human or rat pS2. Peptide is present in dimer form, in which two identical monomers are linked by disulfide bond between two cysteine residues. Molecular weight of peptide is close to 13000. Appropriate host cells transformed by DNA encoding human or rat ITF or pS2 are cultured and dimer form is separated from monomer one. Pharmaceutical composition includes &#34;clover&#34; peptide and pharmaceutically acceptable diluent. &#34;Clover&#34; peptide dimer forms are used for preparing drugs useful for healing gastrointestinal way mucosa injuries, e.g. peptic ulcer. EFFECT: facilitated preparation of pharmaceutically active peptides. 15 cl, 13 dwg, 2 tbl, 7 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a makeup cosmetic which can create a preferable expression appearance such as freshness and vivid brightness.  &lt;P&gt;SOLUTION: This makeup cosmetic comprises (1) 60 to 85 mass% of platy powder and (2) 10 to 30 mass% of spherical powder. It is necessary that ≥90 mass% of the spherical powder is monodisperse spherical powder having an average diameter of 2 to 4 μm. Further, the platy powder preferably contains resin-coated titanium mica in an amount of 1 to 5 mass%. In addition, the platy powder preferably contains platy powder coated with a polymer or copolymer produced from methacryloyloxyethyl phosphorylcholine as a constituting monomer. It is preferable that the makeup cosmetic is finishing white powder.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:A coagulation accelerator of blood, containing an organopolysiloxane fluid having one or more monofunctional hydrocarbon groups having a hydroxyl or carboxylic acid group in one molecule as a principal agent, and capable of facilitating the blood chemical test by reducing the blood coagulation time. CONSTITUTION:A coagulation accelerator of blood, containing an organopolysiloxane fluid having at least one monofunctional hydrocarbon group containing a hydroxyl group, e.g. CH2OH, or monofunctional hydrocarbon group containing a carboxylic acid group, e.g. CH2CH2COOH, e.g. formulaI, II or III (R&lt;1&gt; is monofunctional hydrocarbon group contaning OH or COOH; R is monofunctional hydrocarbon group containing no OH or COOH; m is an integer &gt;=0; n is an integer &gt;=1; k is 1, 2 or 3; l is an integer 1-4; k+l=4) as a principal agent, and having a viscosity of 10-50,000cSt at 25 deg.C. The agent has a coagulation accelerating action on blood absent in the usual organopolysiloxane, and capable of reducing the time of standing required for the separation of blood serum.
NEW MATERIAL:A compound of the formula (X is amino-protecting group, H; Y is carboxyl-protecting group, H) and its salt. EXAMPLE:Boc-Trp(CHO)-Arg-OMe acetate. USE:It is used as a medicine, because of its analgesic action. PREPARATION:N-Boc-N&lt;1&gt;-Trp(CHO),Arg-OMe.2HCl and HOBT are dissolved in DMF and Et3N and DCC are added, then they are stirred. The precipitate is filtered off, n-BuOH is added to the mother liquor, further conc. ammonium acetate solution is added to separate the n-BuOH layer. The layer is concentrated under reduced pressure and petroleum ether is added to the remainder to give an oil product. Then, the product is dried under reduced pressure, dissolved in 2N acetic acid, passed through Dowex 1X2 (acetate type) column, the adsorbate is washed with water, purified and freeze dried to give the exemplified compound Boc is a t-butoxy carbonyl group.
The present invention relates to a system and method for predicting medication adherence risk using machine learning. After providing a voice counseling service to a patient or guardian and extracting effective information, which is meaningful information necessary for extracting the patient&#39;s medication compliance risk, from the voice counseling, the extracted effective information and the collected MyData (financial transaction, communication fee payment, etc.) are analyzed to output the patient&#39;s medication compliance risk, by using the medication compliance risk extraction algorithm, which is a learned machine learning algorithm. Based on the medication compliance risk information printed out, a medication compliance report is generated and provided to the medical staff, so that the medical staff consults the medication compliance report by referring to the medication compliance report. Not only can a patient&#39;s medication compliance be dramatically increased, but also the medical cost consumption due to the conventional low medication compliance can be reduced. It is possible to maximize consultation concentration, efficiency and effect compared to the same consultation time. It is possible to reduce the unnecessary budget consumption of the insurance company.
&lt;P&gt;PROBLEM TO BE SOLVED: To enhance the effect of preventing medical accidents by appropriately arranging check items for the prevention of medical accidents by means of the frequencies of occurrence of accidents about direction information input by a physician or the like to an electronic chart system, and then presenting the items and the direction information at the same time on a practioner&#39;s terminal.  &lt;P&gt;SOLUTION: Based on the direction information input from the electronic chart input/output part 101 of the electronic chart system, an alignment check item creating part 202 searches a check item database 203 for the check items related to the direction information. Based on the check items searched for, an accident statistic processing part 204 tallies the frequencies of occurrence for each check item from an accident database 205. Based on the tallied frequencies of occurrence of accidents for each check item, the order of the check items is rearranged and the check items are presented to a medical accident prevention information input/output part 207 in association with the direction information. The medical accident prevention support system is achieved, that is capable of more effectively reducing the risks of medical accidents by checking items in the order preferentially from the check item associated with the highest risk of medical accidents.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
NEW MATERIAL:An indane derivative expressed by formula I a or I b (R&lt;2&gt; and R&lt;3&gt; are H, lower alkyl or halogen, provided that R&lt;2&gt; and R&lt;3&gt; in formula I a are not H at the same time) and a salt thereof. EXAMPLE:7-Hydroxy-4-methyl-1-indanone oxime. USE:An antioxidant, having the ability to remove active oxygen species and prevent the formation of lipoperoxides in the living body, and specifically useful as an antiarteriosclerotic agent, carcinogenic preventing agent, carcinostatic agent, anti-inflammatory agent, analgesic agent and remedy for autoimmune diseases, etc. PREPARATION:A compound expressed by formula 2 is reacted with a compound expressed by formula 3 in the presence or absence of a basic compound, e.g. NaOH, in an inert solvent, e.g. methanol or dioxane, to afford the aimed compound expressed by formula I a, which is then catalytically hydrogenated in the presence of a catalyst, e.g. Pd, to give the compound expressed by formula I b.
PROBLEM TO BE SOLVED: To obtain the subject agent that can inhibit the steep increase of blood sugar level after the meal to reduce the load on the pancreatic β-cells, can be utilized in the dietary therapy for patients with insulin-independent diabetes and can reduce the absorption of blood sugar after loading of glucose by using Cirsium martimum Makino and/or its extract. SOLUTION: The objective blood sugar increase suppressor comprises Cirsium maritimum Makino and/or its extract. The active ingredient is preferably cirsimarin represented by the formula. The extract is obtained by using water, ethanol or the like as a solvent. The deily dose of this hypoglyemic agent is &gt;=1.0 g/kg body weight as the dried solid of the plant, while the dose is &gt;=10 mg/kg body weight in the case of the extract. This inhibitor is given to the patients in the preparation form of a liquid dispersion, a soft extract or the like, further excipient, adjuvant and the like may be admixed into powder, granules and the like.
The PC based ultrasound system utilizes a standard PC central processing unit or CPU (an Intel 486 processor or better), standard PC memory storage and retrieval components, a scan conversion board and a video processing board, all disposed and electronically linked to the bus in the computer. Additionally, the analog drive and return scan video signals are sent to and received from a video processing and motor control unit. The video processing and motor control unit is coupled to an ultrasound scan lead or probe. The virtual control user interface for the ultrasound system includes a software driven display obtained from memory. The software driven display reveals images representative of hardware control configurations for many different ultrasound processors. The images provided by the software driven display include: gain control tactile user interfaces, image enhancement control tactile user interfaces, focus control tactile user interface, multiple menu levels for gain control, image enhancement, and focus controls. In a further embodiment, the virtual control user interface is used in conjunction with a touch sensitive user input screen and the virtual control user interface includes a touch screen input command converter responsive to a user&#39;s touch on the touch sensitive display monitor to convert the tactile input into software commands. Other features include the ability to recall previously scanned ultrasound images, annotate recently acquired ultrasound images, preferably in color, electronically transfer the images to other peripheral computer equipment, and display a checklist for medical protocol involved in the ultrasound medical techniques. The medical protocol is loaded as pull down or pop up menu available to the user.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a food or a medicine taken daily and continuously, and exhibiting safe and sufficient antiallergic effects.  &lt;P&gt;SOLUTION: The antiallergic agent contains an extract of a leaf of olive and an extract of oolong stem tea. A commercial product can be utilized as the extract of the leaf of the olive. The dietary intake of the extract of the leaf of the olive and the extract of the oolong stem tea is different based on the shape, symptom, age, body weight or the like, but the intake of the extract of the leaf of the olive is 1-1,000 mg/day, preferably, 5-200 mg/day, and the intake of the oolong stem tea is 1-1,000 mg/day, preferably 5-500 mg/day. The dose form of the allergic agent is unlimited, and a normal form of a food and a medicine such as a tablet sweet, a candy, a granule and a beverage can be adopted.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE: To obtain an X-ray contrast compsn. prepared by incorporating a polymer film-forming substance containing a specified nonion X-ray contrast medium and bivalent metal ions into a carrier so that an effective coating film which does not transmit radiation can be forming on the inner wall of gastrointestinal organs of mammals. CONSTITUTION: This X-ray contrast compsn. is used by oral dose and for scanning inspection and is prepared by incorporating a film-forming substance containing bivalent cations such as Ca&lt;++&gt; , Mg&lt;++&gt; , Zn&lt;++&gt; and Ba&lt;++&gt; and consisting of a polymer material which can form a coating film on the inner wall of gastrointestinal organs, and a nonionic X-ray contrast medium expressed by formula I (R is a substd. or unsubstd. 1 to 6C alkyl group and (n) is an integer 1 to 5) into a pharmaceutically allowable carrier. The polymer material consists of a compd. expressed by formulae II to IV (R represented a polymer chain and M&lt;++&gt; is a bivalent cation) and is produced by using methylcellulose, polyvinylpyrolidone, etc. As for the X-ray contrast medium, a compd. expressed by formula V is preferable. As for the medicinal carrier, a cationic, anionic, bipolar or nonionic surfactant can be used.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain protein-associated iron that improves absorption ratio of iron in the human body and reduces gastrointestinal injury by iron.  &lt;P&gt;SOLUTION: The protein-associated iron comprises dark meat part of dried fish abundantly containing protein as a raw material and is obtained by adding the raw material, protease and an iron material to water, stirring the mixture and allowing it to stand so as to subject it to enzymatic hydrolysis. The protein in the raw material is combined with iron by enzymatic hydrolysis with protease to give protein-associated iron. Iron is absorbed in the body by internal use of protein-associated iron more efficiently than direct internal use of heme iron and ferrous sulfate. Since protein is combined with iron, gastrointestinal injury by iron is reduced.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Database of patient specific electronic health records indexed by ICD or CPT medical coding protocols or similar. The indexing allows organization of the patient&#39;s records within the database by health diagnoses, treatments or tests. This method facilitates rapid searching and retrieval of past diagnoses, etc. for utilization in diagnosis, treatment or testing of the patient in subsequent medical events. The method allows a clinician or health care provider to rapidly learn whether a patient has a history of prior treatment for the symptoms now experienced. The software and method can be utilized to search billing records wherein the ICD or similar codes have been recorded and then match the coded events to events contained in the patient&#39;s EHR database. This allows searching of the EHR database utilizing diagnosis, treatment and test codes in situations where old patient records stored in the database have not adopted the code indexing.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a humectant having high water solubility and excellent humectant properties, and an external preparation for the skin, using the humectant.  &lt;P&gt;SOLUTION: The humectant comprises a polyuronic acid obtained by selectively converting a primary hydroxy group of a polysaccharide to a carboxy group or a salt thereof by oxidizing the polysaccharide. The external preparation for the skin contains the humectant. The polyuronic acid obtained by oxidizing the polysaccharide comprising N-acetylglucosamine or a glucose, e.g. chitin or cellulose is preferably used. The weight average molecular weight of the polyuronic acid is preferably within the range of 5,000-200,000.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a stable oxidative dyestuff composition containing a cationic polymer.  &lt;P&gt;SOLUTION: This composition for oxidatively dyeing a keratin fiber, especially human keratin fiber, e.g. hair is characterized by containing the following components in a medium suitable for the dyeing. (a) At least one oxidative dyestuff. (b) At least one fatty alcohol. (c) At least one associative polymer. (d) At least one 14-30C alkyl sulfate. The oxidative dyestuff composition has a satisfactory consistency and a stable viscosity for a long period without increasing the content of the fatty alcohol or using other thickening agent of a cross-linked polyacrylic acid type.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain the powder having both effects of giving good texture and color to a skin and suitable for cosmetics by incorporating a dye into silica. SOLUTION: A dye. preferably a yellow dye (e.g. yellow iron oxide, yellow No.4 aluminum chelate) is incorporated into silica by preferably 0.1 to 30 wt.%, more preferably 0.5 to 25 wt.%, and further preferably 1 to 20 wt.%. The powder can be produced, for example, by dissolving or dispersing a silicate such as sodium silicate and a dye in an aq. carrier and/or a lower alcohol as a solvent, adding an acid to produce a silica gel, taking out the silica gel, cleaning the gel, and heating to remove the solvent. The powder has 0.01 to 20 μm average particle size, preferably 0.05 to 15 μm, and especially preferably 0.1 to 10 μm. If necessary, a powder material such as tale can be added as an optional component, however, it is not preferable when the silica purity decreases to &lt;70%.
The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP&#39;s), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified aminoterminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. WO 2004/078 140 PCT/US2004/006656 On Q -P )Z4 N&gt;4 1t1